Savella (milnacipran HCl, from Forest Laboratories and Cypress Bioscience), a selective serotonin and norepinephrine dual reuptake inhibitor, approved for the management of fibromyalgia, will be shipped to wholesalers on April 24, 2009 and will be available in pharmacies beginning April 28, 2009. Savella initially received approval on January 14, 2009, after which the companies submitted a minor post-approval cosmetic formulation change that has since been FDA approved.

For more information call (800) 678-1605 or visit